MedTrace Logo

EFFORT Further Extension Study

NCT02826070 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2016-07-07

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that long-term treatment (up to six years) with telbivudine or telbivudine plus adefovir results in the regression in liver inflammation and fibrosis/cirrhosis.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Telbivudine

Telbivudine, 600mg, oral, daily

DRUG

Adefovir dipivoxil

Adefovir dipivoxil 10mg, oral, daily

OTHER

off-treatment follow-up

Sponsors & Collaborators

  • Major Science and Technology Special Project of China Twelfth-Five-Year Project

    collaborator UNKNOWN

  • Novartis

    collaborator INDUSTRY

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Jinlin Hou · Nanfang Hospital, Southern Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-10-31
Completion
2017-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02826070 on ClinicalTrials.gov